Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255968 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02255968 is a Phase 1 study that was terminated before completion, run by Enanta Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT02255968, a Phase 1 study, was terminated before completion, sponsored by Enanta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the safety and tolerability of multiple doses of orally administered EDP-788. Secondary objectives of the study are to describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after multiple doses of orally administered drug.
Interventions
- DRUG Placebo
- DRUG EDP-788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255968
The ClinicalTrials.gov registry entry for NCT02255968 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02255968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255968 about?
NCT02255968 is a clinical study titled "Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788". The primary objective of the study is to determine the safety and tolerability of multiple doses of orally administered EDP-788. Secondary objectives of the study are to describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after multiple doses of orally administered drug.
What is the current status of trial NCT02255968?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02255968?
The interventions under investigation include: Placebo (DRUG), EDP-788 (DRUG).
Who is sponsoring clinical trial NCT02255968?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.